Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009–2010.

<p>Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009–2010.</p

Multivariate associations^* between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.

<p>Multivariate associations^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186087#t004fn002" target="_blank">*</a>} between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.</p

Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009–2010.

<p>Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009–2010.</p

Baseline characteristics of older adults based on prevalent and incident frailty, the Three-City study, Bordeaux, 2009–2010.

<p>Baseline characteristics of older adults based on prevalent and incident frailty, the Three-City study, Bordeaux, 2009–2010.</p

Additional file 1: of The evaluation of off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale

Members of the ORTHODIAB Collaborative Group. (DOCX 56 kb

Additional file 1: of Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case–control study

The questionnaire used in the current study. (PDF 620 kb

Characteristics of samples successfully analyzed in each discovery collection and the meta-analyses.

<p>n = total number of patients; Micro = patients with microalbuminuria; M/F = number of males/females; HbA_1C blood glycosylated hemoglobin; BMI = body mass index. Case = macroalbuminuria or ESRD, Control = normoalbuminuric, see text for full details.</p

Forest plots for significant hits incorporating discovery and replication plots.

<p>Plots show the study-specific association estimates (OR) and 95% confidence intervals for the discovery and second phase studies. (A) Association of rs7583877 with ESRD; heterogeneity <i>P</i> = 0.037. (B) Association of rs12437854 with ESRD; heterogeneity <i>P</i> = 0.046. (C) Association of rs7588550 with DN; heterogeneity <i>P</i> = 0.467. The association estimate and confidence interval for the meta-analysis combining the discovery and second-stage results are denoted by the diamond.</p

Results from discovery, second stage, and combined meta-analysis for supported markers.

<p>A1 = minor allele = effect allele; A2 = major allele; Freq(A1) = minor allele frequency; OR = odds ratio; 95% CI = 95% confidence interval. Discovery: Meta analysis results for GENIE discovery cohorts. Stage 2: Meta analysis results for replication cohorts. Combined: Meta analysis results for discovery and the stage 2 cohorts. NA = no result, due to genotype failure or quality control filtering.</p

Flow chart summarizing study design.

<p>We applied a two stage study design, where the top signals from the meta-analysis of three GENIE studies (UK-ROI, FinnDiane and GoKinD US) were followed up in phase two analysis, consisting of nine T1D cohorts. After combined meta-analysis, two signals reached genome-wide significance in the analysis of ESRD (<i>P</i><5×10⁻⁸). For DN phenotype no loci reached this threshold, but the strongest association was observed for <i>ERBB4</i>. These signals were followed up with eQTL studies and functional analysis. The number of patients (N) refers to the number of samples after genotype quality control; either the total number of samples or divided into cases/controls.</p